Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eggehard Holler
Cedars Sinai Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Arrogene, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Arrogene has patents related to the technology behind the design and use of the bioconjugates that will be utilized in this Study. However, at the same time, Arrogene has no plans to produce such nanoconjugates for commercial use.
Nano immunoconjugates to treat primary and metastatic HER2 positive breast cancer
PROJECT NARRATIVE Breast cancer is the second cause of cancer death among women in the United States; breast tumors overexpressing the HER2/neu receptor are aggressive with high frequency of metastasis, and are number one among breast cancer types metastasizing to the brain. Our goal is to introduce new nano immunoconjugates (NIC) with attached checkpoint inhibitors (monoclonal antibodies) that boost immune microenvironment of breast cancers and their brain metastases. Contrary to free checkpoint inhibitor antibodies, our nano drugs will cross the blood-brain barrier and activate not only systemic but also local anti-tumor immune response.
Filed on January 14, 2019.
Tell us what you know about Eggehard Holler's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Eggehard Holler”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | $10,000 - $19,999 |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | $10,000 - $19,999 |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | Value cannot be readily determined |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | $10,000 - $19,999 |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | $10,000 - $19,999 |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | Value cannot be readily determined |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | Value cannot be readily determined |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | Value cannot be readily determined |
| Eggehard Holler | Cedars Sinai Medical Center | Conflict of Interest | Arrogene, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.